<DOC>
	<DOC>NCT00664716</DOC>
	<brief_summary>Safety and efficacy of BG9924 in RA participants that have had an inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy.</brief_summary>
	<brief_title>Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Key Diagnosis of RA (functional class I III) Stable dose of MTX Inadequate response to at least one conventional DMARD therapy Key Serious local infection or systemic infection History (Hx) of recurrent infections requiring oral or parenteral antiinfective treatment Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the screening period Clinical significant lab tests at screening Positive for Hep C or Hep B at screening NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>DMARD inadequate response</keyword>
	<keyword>Methotrexate</keyword>
</DOC>